One challenge for innovators at MSK and elsewhere is that technology development is costly and funding options are limited—especially once the potential for federal grant funding has been exhausted.
The invention, rapid manufacturing and distribution of the COVID-19 vaccine demonstrates exactly how fast the life sciences treatment development pipeline can move when the right factors are in play.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback